Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

E. Sands, Bruce; J. Sandborn, William; Panaccione, Remo; D. O’Brien, Christopher; Zhang, Hongyan; Johanns, Jewel; J. Adedokun, Omoniyi; Li, Katherine; Peyrin‐Biroulet, Laurent; Van Assche, Gert; Danese, Silvio; R. Targan, Stephan; T. Abreu, María; Hisamatsu, Tadakazu; Szapary, Philippe; Marano, Colleen

doi:10.1056/nejmoa1900750

Public

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Published in New England Journal of Medicine • Sep 25, 2019

Authors:

Bruce E. Sands

William J. Sandborn

Remo Panaccione

Abstract

BACKGROUND The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown. METHODS We evaluated ustekinumab as 8-week induction therapy and 44-week maintenance therapy in patients...

Subject

Ustekinumab

Medicine

Maintenance therapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!